Anti-HIV drug update.

Project Inform perspective

PubMedID: 12769050

Slow but steady progress continues on a number of new anti-HIV drugs in the three drug classes. If approved, some of these represent true second-generation therapies that will offer some degree of advance over current drugs. Others are not that much different from today's drugs. The article below combines information from the most recently announced studies, including those presented at the 7th Conference on Retroviruses and Opportunistic Infections.